Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Clinician-Selected FSH Starting Dose and Mature Oocyte Yield in Predicted Poor Responders (OPTIMAL-DOSE)

17 listopada 2026 zaktualizowane przez: Goksu Goc, American Hospital 2 Kosovo

Association of Clinician-Selected FSH Starting Dose With Mature Oocyte Yield in Women With Predicted Poor Ovarian Response: The OPTIMAL-DOSE Prospective Cohort Study

This is a single-centre, prospective, non-interventional (observational) cohort study examining the association between the clinician-selected starting dose of follicle-stimulating hormone (FSH) and the yield of mature metaphase II (MII) oocytes in women with predicted poor ovarian response (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number [POSEIDON] group 3 or 4) undergoing in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) with a gonadotropin-releasing hormone (GnRH) antagonist protocol. The FSH dose is chosen by the treating physician as part of routine care; the study does not allocate, randomize, or change treatment. The primary outcome is the number of MII oocytes per initiated index cycle. Because dosing is not randomized, analyses are adjusted for measured confounders and address confounding by indication.

Przegląd badań

Status

Jeszcze nie rekrutacja

Warunki

Interwencja / Leczenie

Szczegółowy opis

Randomized evidence in predicted poor responders (a randomized trial in predicted poor responders and the 2024 Cochrane review of individualised gonadotropin dosing) does not show improved live birth from higher follicle-stimulating hormone (FSH) dosing, so this cohort is not designed to establish comparative efficacy; its contribution is a description of real-world dose-response patterns and local gonadotropin use and cost. Consecutive eligible women are enrolled after informed consent for data use, each contributing one index cycle. The exposure is the clinician-selected starting FSH dose, analysed as a continuous variable (per 75 international units [IU]), with categories of 150 IU or less versus more than 150 IU reported descriptively and in sensitivity analyses. The primary analysis is an adjusted negative-binomial regression of the metaphase II (MII) oocyte count on exposure, with adjusted means obtained by marginal standardization and an overlap-weighted propensity analysis as sensitivity. Reporting follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) and REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statements.

Typ studiów

Obserwacyjny

Zapisy (Szacowany)

160

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Lokalizacje studiów

      • Pristina, Kosowo, 10000
        • American Hospital Kosova
        • Kontakt:

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat do 42 lata (Dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Kobieta

Metoda próbkowania

Próbka bez prawdopodobieństwa

Badana populacja

Consecutive women aged 18 to 42 years with predicted poor ovarian response (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number (POSEIDON) group 3 or 4: anti-Mullerian hormone below 1.2 ng/mL and/or antral follicle count below 5) undergoing a gonadotropin-releasing hormone (GnRH) antagonist in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle as part of routine clinical care at American Hospital Kosova, each contributing one index cycle.

Opis

Inclusion Criteria:

  1. Woman aged 18 to 42 years.
  2. Predicted poor ovarian response, Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number (POSEIDON) group 3 (under 35 years) or group 4 (35 years or older): anti-Mullerian hormone (AMH) below 1.2 ng/mL and/or antral follicle count (AFC) below 5 (both ovaries combined).
  3. Planned gonadotropin-releasing hormone (GnRH) antagonist in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle as part of routine clinical care.
  4. First eligible (index) cycle during the study period; both ovaries present.
  5. Written informed consent for data collection and processing.

Exclusion Criteria:

  1. Predicted normal or high ovarian reserve (AMH 1.2 ng/mL or higher and AFC 5 or higher).
  2. Non-antagonist protocol (for example, long GnRH-agonist).
  3. Oocyte-donation or fertility-preservation (egg-freezing) cycle.
  4. A prior cycle of the same woman already enrolled in the study.
  5. Inability to provide informed consent.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Modele obserwacyjne: COHORT
  • Perspektywy czasowe: PROSPECTIVE

Kohorty i interwencje

Grupa / Kohorta
Interwencja / Leczenie
Lower starting dose (150 international units [IU] or less)

Women whose treating physician chose a starting daily follicle-stimulating hormone (FSH) dose of 150 international units (IU) or less as part of routine clinical care (observed, not assigned by the study).

FSH administered per routine clinical practice; the starting dose is selected by the treating physician (observed exposure, not assigned by the study). Starting dose is analysed continuously (per 75 IU), with categories of 150 IU or less versus more than 150 IU reported descriptively.

Higher starting dose (more than 150 IU)

Women whose treating physician chose a starting daily FSH dose of more than 150 IU (typically 225 IU) as part of routine clinical care (observed, not assigned by the study).

FSH administered per routine clinical practice; the starting dose is selected by the treating physician (observed exposure, not assigned by the study). Starting dose is analysed continuously (per 75 IU), with categories of 150 IU or less versus more than 150 IU reported descriptively.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Number of mature metaphase II (MII) oocytes retrieved
Ramy czasowe: On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)

Number of metaphase II (MII) oocytes retrieved per initiated index ovarian stimulation cycle, assessed by the embryologist at a standardized time after oocyte retrieval. Compared across the clinician-selected starting-dose exposure using adjusted analysis (associations, not causal effects). Cycles cancelled before oocyte retrieval contribute zero MII oocytes in the initiated-cycle analysis. Oocytes matured in vitro are excluded from the primary count.

On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Total follicle-stimulating hormone (FSH) activity administered
Ramy czasowe: From the first to the last day of ovarian stimulation (up to 21 days)

Total follicle-stimulating hormone (FSH) activity administered during the index stimulation cycle, in international units (IU), by observed starting-dose exposure. FSH activity is recorded separately from luteinizing hormone (LH) and human chorionic gonadotropin (hCG) activity.

From the first to the last day of ovarian stimulation (up to 21 days)
Gonadotropin medication cost
Ramy czasowe: From the first to the last day of ovarian stimulation (up to 21 days)

Cost of the gonadotropin medication used during the stimulation cycle, in euros (EUR), calculated using a pre-specified standardized unit-price table, by observed starting-dose exposure.

From the first to the last day of ovarian stimulation (up to 21 days)
Total number of oocytes retrieved
Ramy czasowe: On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)

Total number of oocytes retrieved at oocyte pick-up per initiated index cycle, by observed starting-dose exposure.

On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)
Oocyte maturity rate
Ramy czasowe: On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)

Ratio of the number of metaphase II (MII) oocytes to the total number of oocytes retrieved in the index cycle, by observed starting-dose exposure.

On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)
Cycle cancellation before oocyte retrieval
Ramy czasowe: From the first day of ovarian stimulation to the planned day of oocyte retrieval (up to 21 days)

Whether the initiated index cycle was cancelled before oocyte retrieval, by observed starting-dose exposure.

From the first day of ovarian stimulation to the planned day of oocyte retrieval (up to 21 days)
Duration of ovarian stimulation
Ramy czasowe: From the first to the last day of ovarian stimulation (up to 21 days)

Number of days of ovarian stimulation during the index cycle, by observed starting-dose exposure.

From the first to the last day of ovarian stimulation (up to 21 days)
Number of normally fertilised oocytes with two pronuclei (2PN)
Ramy czasowe: At the fertilisation check, 1 day after oocyte retrieval (up to 22 days after the start of ovarian stimulation)

Number of oocytes showing two pronuclei (2PN) at the fertilisation check in the index cycle, by observed starting-dose exposure.

At the fertilisation check, 1 day after oocyte retrieval (up to 22 days after the start of ovarian stimulation)
Number of usable embryos
Ramy czasowe: Up to 6 days after oocyte retrieval (up to 27 days after the start of ovarian stimulation)

Number of embryos from the index cycle that are transferred, cryopreserved or biopsied, meeting the minimum grade of the pre-specified laboratory standard, by observed starting-dose exposure. Each embryo is counted once.

Up to 6 days after oocyte retrieval (up to 27 days after the start of ovarian stimulation)
Number of blastocysts
Ramy czasowe: Up to 6 days after oocyte retrieval (up to 27 days after the start of ovarian stimulation)

Number of embryos from the index cycle reaching the blastocyst stage, by observed starting-dose exposure.

Up to 6 days after oocyte retrieval (up to 27 days after the start of ovarian stimulation)

Inne miary wyników

Miara wyniku
Opis środka
Ramy czasowe
Live birth (exploratory)
Ramy czasowe: Up to 12 months after the start of ovarian stimulation

Delivery of at least one live-born infant, recorded per initiated index cycle and per transfer. Exploratory only; the study is not powered for this outcome and it is highly susceptible to confounding by indication. Reported descriptively.

Up to 12 months after the start of ovarian stimulation
Clinical pregnancy (exploratory)
Ramy czasowe: At 7 weeks of gestation (approximately 5 weeks after the first embryo transfer)

Presence of an intrauterine gestational sac on ultrasound after the first fresh or frozen embryo transfer from the index cycle, recorded per initiated index cycle and per transfer. Exploratory only; the study is not powered for this outcome. Reported descriptively.

At 7 weeks of gestation (approximately 5 weeks after the first embryo transfer)

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

1 listopada 2026

Zakończenie podstawowe (Szacowany)

1 października 2028

Ukończenie studiów (Szacowany)

1 sierpnia 2029

Daty rejestracji na studia

Pierwszy przesłany

11 listopada 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

17 listopada 2026

Pierwszy wysłany (Rzeczywisty)

18 listopada 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

18 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

17 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • OPTIMAL-DOSE-OBS-2026-001

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .